Lexicon Pharmaceuticals’ (LXRX) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note published on Monday,Benzinga reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $2.50.

Lexicon Pharmaceuticals Price Performance

NASDAQ LXRX opened at $0.34 on Monday. Lexicon Pharmaceuticals has a one year low of $0.28 and a one year high of $2.83. The stock has a 50-day moving average of $0.74 and a 200 day moving average of $1.16. The company has a market capitalization of $82.74 million, a price-to-earnings ratio of -0.45 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Lexicon Pharmaceuticals by 193.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 353,508 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 233,121 shares during the last quarter. Tang Capital Management LLC boosted its position in Lexicon Pharmaceuticals by 750.3% in the fourth quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 750,268 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of Lexicon Pharmaceuticals by 630.7% during the 4th quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after buying an additional 7,758,371 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Lexicon Pharmaceuticals by 378.0% during the 4th quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 249,616 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Lexicon Pharmaceuticals by 27.4% during the 4th quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 29,319 shares in the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.